What is it about?
We aimed to investigate the levels of receptor activator of nuclear factor-kappa-b ligand (RANKL) and osteoprotegerin (OPG) to evaluate the negative effects of type 2 diabetes mellitus on bone health and their relationship to the severity of disease based on the treatment. We also evaluated the relationship between hemoglobin A1c (HbA1c), parathyroid hormone (PTH) and bone-specific alkaline phosphatase (BAP) levels and RANKL and OPG levels.
Featured Image
Why is it important?
We believe that RANKL and OPG levels are higher in patients with poor glycemic control and that they may be indicators of disease severity.
Perspectives
OPG may confer benefits in determining and monitoring the DM2-dependent bone quality deterioration, and risk stratification of fractures in diabetics.
Muhammed Emin DÜZ
Amasya Universitesi
Read the Original
This page is a summary of: Evaluation of Receptor Activator of Nuclear Factor Kappa-B Ligand and Osteoprotegerin Levels in Patients with Type 2 Diabetes Mellitus Treated with Oral Anti-Diabetic (Sulfonylurea and Metformin) or Insulin from the Perspective of Bone, Istanbul Medical Journal, January 2019, Journal of Clinical Research of Pediatric Endocrinology,
DOI: 10.4274/imj.04657.
You can read the full text:
Resources
Contributors
The following have contributed to this page
